Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, December 20, 2014
 
Register | Sign in
Home Page>Products
  Product News
Activ8rlives to Develop its First Medical Smartwatch
Friday, December 19, 2014
BuddyWOTCH for continuous monitoring of oxygenation for UK’s Chronic Obstructive Pulmonary Disease patients.

Ebola Antigens and Antibodies for ELISA
Friday, December 19, 2014
AMSBIO products for the development of an ELISA detection assay for the Ebola virus.

Exiqon Launches Two New Research Use Only Kits
Friday, December 19, 2014
The miRSIGN™ miR-21 Oncogene assay and the miRSIGN™ Colon Cancer assay for PCR analysis of colon cancer samples.

Bruker Releases ONET Software
Thursday, December 18, 2014
New networking software for administration of FT-NIR spectrometer networks.

New Tool for High Strain Rate Materials Testing
Thursday, December 18, 2014
Specialized Imaging Kirana camera create high-resolution images of the ultra high-speed events.

Breaking Barriers in siRNA Delivery
Wednesday, December 17, 2014
Discover a new approach to transfection in the latest DECODED article from IDT.

Revolutionize Routine Medical Testing with Latest ‘Super-Control’ from Randox
Wednesday, December 17, 2014
'Super Control' will revolutionize quality control in laboratories.

ONET Software Released
Wednesday, December 17, 2014
Bruker releases ONET Software for administration of FT-NIR spectrometer networks.

INTEGRA Focus on Liquid Handling at SLAS 2015
Tuesday, December 16, 2014
INTEGRA's VIAFLO 96 and VIAFLO 384 benchtop electronic pipettes will be on display.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 10725
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn